$LGND Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in LIGAND PHARMACEUTICALS INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in LIGAND PHARMACEUTICALS INC. Get notifications about new insider transactions in LIGAND PHARMACEUTICALS INC for free.
Page: < prev 1 ... 2 3 4 5 6 7 8 9 ... 15 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Feb 16 2016 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | A | 85.79 | 55,391 | 4,751,994 | 55,391 | |
Feb 16 2016 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Payment of Exercise | F | 85.97 | 2,492 | 214,237 | 130,497 | 133 K to 130.5 K (-1.87 %) |
Feb 16 2016 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Grant | A | 0.00 | 11,611 | 0 | 132,989 | 121.4 K to 133 K (+9.57 %) |
Feb 16 2016 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Option Exercise | A | 85.79 | 27,080 | 2,323,193 | 27,080 | |
Feb 16 2016 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Payment of Exercise | F | 85.97 | 1,642 | 141,163 | 76,662 | 78.3 K to 76.7 K (-2.10 %) |
Feb 16 2016 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Grant | A | 0.00 | 5,676 | 0 | 78,304 | 72.6 K to 78.3 K (+7.82 %) |
Feb 16 2016 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | VP, Finance and CFO | Option Exercise | A | 85.79 | 18,464 | 1,584,027 | 18,464 | |
Feb 16 2016 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | VP, Finance and CFO | Grant | A | 0.00 | 3,870 | 0 | 9,870 | 6 K to 9.9 K (+64.50 %) |
Feb 16 2016 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Option Exercise | A | 85.79 | 10,463 | 897,621 | 10,463 | |
Feb 16 2016 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Grant | A | 0.00 | 2,193 | 0 | 29,647 | 27.5 K to 29.6 K (+7.99 %) |
Feb 16 2016 | LGND | LIGAND PHARMACEUTI ... | Herman Melanie J | Director of Account ... | Option Exercise | A | 85.79 | 5,000 | 428,950 | 5,000 | |
Feb 16 2016 | LGND | LIGAND PHARMACEUTI ... | Herman Melanie J | Director of Account ... | Payment of Exercise | F | 85.97 | 160 | 13,755 | 3,631 | 3.8 K to 3.6 K (-4.22 %) |
Feb 16 2016 | LGND | LIGAND PHARMACEUTI ... | Herman Melanie J | Director of Account ... | Grant | A | 0.00 | 500 | 0 | 3,791 | 3.3 K to 3.8 K (+15.19 %) |
Apr 15 2016 | LGND | LIGAND PHARMACEUTI ... | LIGAND PHARMACEUTICALS INC | 10% Owner | Option Exercise | J | 0.00 | 150,000 | 0 | 1,955,139 | |
Apr 15 2016 | LGND | LIGAND PHARMACEUTI ... | LIGAND PHARMACEUTICALS INC | 10% Owner | Option Exercise | C | 1.50 | 960,000 | 1,440,000 | 1,520,000 | |
Apr 15 2016 | LGND | LIGAND PHARMACEUTI ... | LIGAND PHARMACEUTICALS INC | 10% Owner | Option Exercise | C | 0.00 | 600,000 | 0 | 2,105,139 | |
Apr 15 2016 | LGND | LIGAND PHARMACEUTI ... | LIGAND PHARMACEUTICALS INC | 10% Owner | Option Exercise | A | 1.50 | 560,000 | 840,000 | 560,000 | |
Apr 15 2016 | LGND | LIGAND PHARMACEUTI ... | LIGAND PHARMACEUTICALS INC | 10% Owner | Buy | C | 1.25 | 960,000 | 1,200,000 | 6,300,964 | 5.3 M to 6.3 M (+17.97 %) |
Apr 15 2016 | LGND | LIGAND PHARMACEUTI ... | LIGAND PHARMACEUTICALS INC | 10% Owner | Grant | A | 0.00 | 560,000 | 0 | 5,340,964 | 4.8 M to 5.3 M (+11.71 %) |
Jan 22 2016 | LGND | LIGAND PHARMACEUTI ... | KOZARICH JOHN W | Director | Option Exercise | M | 59.40 | 1,666 | 98,960 | 0 | |
Jan 22 2016 | LGND | LIGAND PHARMACEUTI ... | KOZARICH JOHN W | Director | Sell | S | 97.99 | 366 | 35,864 | 49,711 | 50.1 K to 49.7 K (-0.73 %) |
Jan 22 2016 | LGND | LIGAND PHARMACEUTI ... | KOZARICH JOHN W | Director | Sell | S | 96.28 | 200 | 19,256 | 50,077 | 50.3 K to 50.1 K (-0.40 %) |
Jan 22 2016 | LGND | LIGAND PHARMACEUTI ... | KOZARICH JOHN W | Director | Sell | S | 94.71 | 200 | 18,942 | 50,277 | 50.5 K to 50.3 K (-0.40 %) |
Jan 22 2016 | LGND | LIGAND PHARMACEUTI ... | KOZARICH JOHN W | Director | Sell | S | 93.83 | 600 | 56,298 | 50,477 | 51.1 K to 50.5 K (-1.17 %) |
Jan 22 2016 | LGND | LIGAND PHARMACEUTI ... | KOZARICH JOHN W | Director | Sell | S | 92.71 | 300 | 27,813 | 51,077 | 51.4 K to 51.1 K (-0.58 %) |
Jan 22 2016 | LGND | LIGAND PHARMACEUTI ... | KOZARICH JOHN W | Director | Buy | M | 59.40 | 1,666 | 98,960 | 51,377 | 49.7 K to 51.4 K (+3.35 %) |
Jan 04 2016 | LGND | LIGAND PHARMACEUTI ... | Herman Melanie J | Director of Account ... | Buy | J | 82.53 | 140 | 11,554 | 3,291 | 3.2 K to 3.3 K (+4.44 %) |
Dec 09 2015 | LGND | LIGAND PHARMACEUTI ... | Davis Todd C | Director | Gift | G | 0.00 | 50 | 0 | 55,399 | 55.4 K to 55.4 K (-0.09 %) |
Nov 13 2015 | LGND | LIGAND PHARMACEUTI ... | Aryeh Jason | Director | Sell | S | 101.49 | 3,000 | 304,470 | 241,836 | 244.8 K to 241.8 K (-1.23 %) |
Nov 13 2015 | LGND | LIGAND PHARMACEUTI ... | Herman Melanie J | Director of Account ... | Option Exercise | M | 74.42 | 2,500 | 186,050 | 3,500 | |
Nov 13 2015 | LGND | LIGAND PHARMACEUTI ... | Herman Melanie J | Director of Account ... | Option Exercise | M | 68.48 | 625 | 42,800 | 3,625 | |
Nov 13 2015 | LGND | LIGAND PHARMACEUTI ... | Herman Melanie J | Director of Account ... | Option Exercise | M | 56.26 | 1,688 | 94,967 | 7,312 | |
Nov 13 2015 | LGND | LIGAND PHARMACEUTI ... | Herman Melanie J | Director of Account ... | Option Exercise | M | 21.92 | 312 | 6,839 | 1,000 | |
Nov 13 2015 | LGND | LIGAND PHARMACEUTI ... | Herman Melanie J | Director of Account ... | Option Exercise | M | 14.47 | 1,500 | 21,705 | 250 | |
Nov 13 2015 | LGND | LIGAND PHARMACEUTI ... | Herman Melanie J | Director of Account ... | Option Exercise | M | 11.91 | 625 | 7,444 | 250 | |
Nov 13 2015 | LGND | LIGAND PHARMACEUTI ... | Herman Melanie J | Director of Account ... | Option Exercise | M | 11.15 | 469 | 5,229 | 0 | |
Nov 13 2015 | LGND | LIGAND PHARMACEUTI ... | Herman Melanie J | Director of Account ... | Sell | S | 101.00 | 7,719 | 779,619 | 3,151 | 10.9 K to 3.2 K (-71.01 %) |
Nov 13 2015 | LGND | LIGAND PHARMACEUTI ... | Herman Melanie J | Director of Account ... | Buy | M | 56.26 | 1,688 | 94,967 | 10,870 | 9.2 K to 10.9 K (+18.38 %) |
Nov 13 2015 | LGND | LIGAND PHARMACEUTI ... | Herman Melanie J | Director of Account ... | Buy | M | 68.48 | 625 | 42,800 | 9,182 | 8.6 K to 9.2 K (+7.30 %) |
Nov 13 2015 | LGND | LIGAND PHARMACEUTI ... | Herman Melanie J | Director of Account ... | Buy | M | 74.42 | 2,500 | 186,050 | 8,557 | 6.1 K to 8.6 K (+41.27 %) |
Nov 13 2015 | LGND | LIGAND PHARMACEUTI ... | Herman Melanie J | Director of Account ... | Buy | M | 21.92 | 312 | 6,839 | 6,057 | 5.7 K to 6.1 K (+5.43 %) |
Nov 13 2015 | LGND | LIGAND PHARMACEUTI ... | Herman Melanie J | Director of Account ... | Buy | M | 14.47 | 1,500 | 21,705 | 5,745 | 4.2 K to 5.7 K (+35.34 %) |
Nov 13 2015 | LGND | LIGAND PHARMACEUTI ... | Herman Melanie J | Director of Account ... | Buy | M | 11.91 | 625 | 7,444 | 4,245 | 3.6 K to 4.2 K (+17.27 %) |
Nov 13 2015 | LGND | LIGAND PHARMACEUTI ... | Herman Melanie J | Director of Account ... | Buy | M | 11.15 | 469 | 5,229 | 3,620 | 3.2 K to 3.6 K (+14.88 %) |
Nov 13 2015 | LGND | LIGAND PHARMACEUTI ... | LAMATTINA JOHN L | Director | Gift | G | 0.00 | 1,500 | 0 | 19,480 | 21 K to 19.5 K (-7.15 %) |
Aug 19 2015 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Sell | S | 95.98 | 4,000 | 383,937 | 66,152 | 70.2 K to 66.2 K (-5.70 %) |
Aug 14 2015 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Sell | S | 96.20 | 7,225 | 695,014 | 30,771 | 38 K to 30.8 K (-19.02 %) |
Aug 14 2015 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Sell | S | 96.20 | 27,300 | 2,626,143 | 196,186 | 223.5 K to 196.2 K (-12.22 %) |
Aug 14 2015 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Sell | S | 96.20 | 2,000 | 192,391 | 969,300 | 971.3 K to 969.3 K (-0.21 %) |
Aug 14 2015 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Sell | S | 96.45 | 2,600 | 250,781 | 37,996 | 40.6 K to 38 K (-6.40 %) |
Aug 14 2015 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Sell | S | 96.45 | 9,875 | 952,486 | 223,486 | 233.4 K to 223.5 K (-4.23 %) |
Aug 14 2015 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Sell | S | 96.45 | 800 | 77,163 | 971,300 | 972.1 K to 971.3 K (-0.08 %) |
Aug 11 2015 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Sell | S | 99.02 | 200 | 19,803 | 40,596 | 40.8 K to 40.6 K (-0.49 %) |
Aug 07 2015 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | VP, Finance and CFO | Option Exercise | A | 104.59 | 25,000 | 2,614,750 | 25,000 | |
Aug 07 2015 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | VP, Finance and CFO | Grant | A | 0.00 | 6,000 | 0 | 6,000 | 0 to 6 K |
Aug 07 2015 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Sell | S | 110.79 | 4,666 | 516,946 | 121,378 | 126 K to 121.4 K (-3.70 %) |
Aug 06 2015 | LGND | LIGAND PHARMACEUTI ... | Davis Todd C | Director | Option Exercise | M | 17.88 | 2,500 | 44,700 | 0 | |
Aug 06 2015 | LGND | LIGAND PHARMACEUTI ... | Davis Todd C | Director | Option Exercise | M | 12.53 | 7,335 | 91,908 | 0 | |
Aug 06 2015 | LGND | LIGAND PHARMACEUTI ... | Davis Todd C | Director | Option Exercise | M | 10.12 | 7,335 | 74,230 | 0 | |
Aug 06 2015 | LGND | LIGAND PHARMACEUTI ... | Davis Todd C | Director | Option Exercise | M | 8.58 | 2,500 | 21,450 | 0 | |
Aug 06 2015 | LGND | LIGAND PHARMACEUTI ... | Davis Todd C | Director | Buy | M | 12.53 | 7,335 | 91,908 | 55,449 | 48.1 K to 55.4 K (+15.25 %) |
Aug 06 2015 | LGND | LIGAND PHARMACEUTI ... | Davis Todd C | Director | Buy | M | 10.12 | 7,335 | 74,230 | 48,114 | 40.8 K to 48.1 K (+17.99 %) |
Aug 06 2015 | LGND | LIGAND PHARMACEUTI ... | Davis Todd C | Director | Buy | M | 8.58 | 2,500 | 21,450 | 40,779 | 38.3 K to 40.8 K (+6.53 %) |
Aug 06 2015 | LGND | LIGAND PHARMACEUTI ... | Davis Todd C | Director | Buy | M | 17.88 | 2,500 | 44,700 | 38,279 | 35.8 K to 38.3 K (+6.99 %) |
Jul 14 2015 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Option Exercise | M | 14.47 | 8,442 | 122,156 | 4,688 | |
Jul 14 2015 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Option Exercise | M | 53.10 | 1,000 | 53,100 | 0 | |
Jul 14 2015 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Option Exercise | M | 10.05 | 5,625 | 56,531 | 0 | |
Jul 14 2015 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Buy | M | 53.10 | 1,000 | 53,100 | 27,454 | 26.5 K to 27.5 K (+3.78 %) |
Jul 14 2015 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Sell | S | 99.86 | 2,825 | 282,105 | 26,454 | 29.3 K to 26.5 K (-9.65 %) |
Jul 14 2015 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Sell | S | 99.18 | 8,838 | 876,553 | 29,279 | 38.1 K to 29.3 K (-23.19 %) |
Jul 14 2015 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Sell | S | 98.15 | 2,404 | 235,953 | 38,117 | 40.5 K to 38.1 K (-5.93 %) |
Jul 14 2015 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Buy | M | 14.47 | 8,442 | 122,156 | 40,521 | 32.1 K to 40.5 K (+26.32 %) |
Jul 14 2015 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Buy | M | 10.05 | 5,625 | 56,531 | 32,079 | 26.5 K to 32.1 K (+21.26 %) |
Jul 01 2015 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Buy | J | 45.67 | 465 | 21,237 | 26,454 | 26 K to 26.5 K (+1.79 %) |
Jul 01 2015 | LGND | LIGAND PHARMACEUTI ... | Herman Melanie J | Interim CFO | Buy | J | 45.67 | 165 | 7,536 | 3,151 | 3 K to 3.2 K (+5.53 %) |
Jun 30 2015 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Option Exercise | M | 9.97 | 2,500 | 24,925 | 92,010 | |
Jun 30 2015 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Option Exercise | M | 9.97 | 12,500 | 124,625 | 94,510 | |
Jun 30 2015 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Buy | M | 9.97 | 2,500 | 24,925 | 72,628 | 70.1 K to 72.6 K (+3.56 %) |
Jun 30 2015 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Sell | S | 100.97 | 12,500 | 1,262,125 | 70,128 | 82.6 K to 70.1 K (-15.13 %) |
Jun 30 2015 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Buy | M | 9.97 | 12,500 | 124,625 | 82,628 | 70.1 K to 82.6 K (+17.82 %) |
Jun 24 2015 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Option Exercise | M | 9.97 | 2,000 | 19,940 | 107,010 | |
Jun 24 2015 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Option Exercise | M | 9.97 | 23,046 | 229,769 | 109,010 | |
Jun 24 2015 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Buy | M | 9.97 | 2,000 | 19,940 | 70,128 | 68.1 K to 70.1 K (+2.94 %) |
Jun 24 2015 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Sell | S | 97.47 | 3,355 | 327,012 | 68,128 | 71.5 K to 68.1 K (-4.69 %) |
Jun 24 2015 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Sell | S | 96.43 | 15,145 | 1,460,432 | 71,483 | 86.6 K to 71.5 K (-17.48 %) |
Jun 24 2015 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Sell | S | 95.77 | 4,546 | 435,370 | 86,628 | 91.2 K to 86.6 K (-4.99 %) |
Jun 24 2015 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Buy | M | 9.97 | 23,046 | 229,769 | 91,174 | 68.1 K to 91.2 K (+33.83 %) |
Jun 11 2015 | LGND | LIGAND PHARMACEUTI ... | Herman Melanie J | Interim CFO | Option Exercise | M | 68.48 | 1,750 | 119,840 | 4,250 | |
Jun 11 2015 | LGND | LIGAND PHARMACEUTI ... | Herman Melanie J | Interim CFO | Option Exercise | M | 21.92 | 875 | 19,180 | 1,312 | |
Jun 11 2015 | LGND | LIGAND PHARMACEUTI ... | Herman Melanie J | Interim CFO | Option Exercise | M | 11.91 | 1,500 | 17,865 | 875 | |
Jun 11 2015 | LGND | LIGAND PHARMACEUTI ... | Herman Melanie J | Interim CFO | Sell | S | 93.50 | 4,125 | 385,688 | 2,986 | 7.1 K to 3 K (-58.01 %) |
Jun 11 2015 | LGND | LIGAND PHARMACEUTI ... | Herman Melanie J | Interim CFO | Buy | M | 68.48 | 1,750 | 119,840 | 7,111 | 5.4 K to 7.1 K (+32.64 %) |
Jun 11 2015 | LGND | LIGAND PHARMACEUTI ... | Herman Melanie J | Interim CFO | Buy | M | 21.92 | 875 | 19,180 | 5,361 | 4.5 K to 5.4 K (+19.51 %) |
Jun 11 2015 | LGND | LIGAND PHARMACEUTI ... | Herman Melanie J | Interim CFO | Buy | M | 11.91 | 1,500 | 17,865 | 4,486 | 3 K to 4.5 K (+50.23 %) |
Jun 11 2015 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Sell | S | 95.06 | 500 | 47,530 | 126,044 | 126.5 K to 126 K (-0.40 %) |
Jun 11 2015 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Sell | S | 93.21 | 3,300 | 307,593 | 126,544 | 129.8 K to 126.5 K (-2.54 %) |
Jun 11 2015 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Sell | S | 92.53 | 6,200 | 573,686 | 129,844 | 136 K to 129.8 K (-4.56 %) |
Jun 08 2015 | LGND | LIGAND PHARMACEUTI ... | Aryeh Jason | Director | Sell | S | 92.68 | 1,640 | 151,995 | 244,836 | 246.5 K to 244.8 K (-0.67 %) |
Jun 01 2015 | LGND | LIGAND PHARMACEUTI ... | LIGAND PHARMACEUTICALS INC | 10% Owner | Buy | J | 0.00 | 228,105 | 0 | 4,780,964 | 4.6 M to 4.8 M (+5.01 %) |
May 20 2015 | LGND | LIGAND PHARMACEUTI ... | Aryeh Jason | Director | Sell | S | 87.65 | 1,000 | 87,650 | 246,476 | 247.5 K to 246.5 K (-0.40 %) |
May 20 2015 | LGND | LIGAND PHARMACEUTI ... | Aryeh Jason | Director | Sell | S | 88.82 | 2,240 | 198,957 | 247,476 | 249.7 K to 247.5 K (-0.90 %) |
May 20 2015 | LGND | LIGAND PHARMACEUTI ... | Aryeh Jason | Director | Sell | S | 86.74 | 6,000 | 520,440 | 249,716 | 255.7 K to 249.7 K (-2.35 %) |
May 18 2015 | LGND | LIGAND PHARMACEUTI ... | KOZARICH JOHN W | Director | Gift | G | 0.00 | 500 | 0 | 49,711 | 50.2 K to 49.7 K (-1.00 %) |
May 14 2015 | LGND | LIGAND PHARMACEUTI ... | DeSilva Nishan M | VP, Finance & Strat ... | Option Exercise | M | 74.42 | 20,938 | 1,558,206 | 24,062 | |
May 14 2015 | LGND | LIGAND PHARMACEUTI ... | DeSilva Nishan M | VP, Finance & Strat ... | Option Exercise | M | 21.92 | 12,148 | 266,284 | 23,546 | |
May 14 2015 | LGND | LIGAND PHARMACEUTI ... | DeSilva Nishan M | VP, Finance & Strat ... | Option Exercise | M | 21.92 | 9,306 | 203,988 | 35,694 | |
May 14 2015 | LGND | LIGAND PHARMACEUTI ... | DeSilva Nishan M | VP, Finance & Strat ... | Option Exercise | M | 14.47 | 11,757 | 170,124 | 64,029 | |
May 14 2015 | LGND | LIGAND PHARMACEUTI ... | DeSilva Nishan M | VP, Finance & Strat ... | Option Exercise | M | 14.47 | 14,214 | 205,677 | 75,786 | |
May 14 2015 | LGND | LIGAND PHARMACEUTI ... | DeSilva Nishan M | VP, Finance & Strat ... | Sell | S | 83.84 | 20,938 | 1,755,442 | 22,282 | 43.2 K to 22.3 K (-48.45 %) |
May 14 2015 | LGND | LIGAND PHARMACEUTI ... | DeSilva Nishan M | VP, Finance & Strat ... | Buy | M | 74.42 | 20,938 | 1,558,206 | 43,220 | 22.3 K to 43.2 K (+93.97 %) |
May 14 2015 | LGND | LIGAND PHARMACEUTI ... | DeSilva Nishan M | VP, Finance & Strat ... | Sell | S | 83.32 | 11,757 | 979,593 | 22,282 | 34 K to 22.3 K (-34.54 %) |
May 14 2015 | LGND | LIGAND PHARMACEUTI ... | DeSilva Nishan M | VP, Finance & Strat ... | Buy | M | 14.47 | 11,757 | 170,124 | 34,039 | 22.3 K to 34 K (+52.76 %) |
May 14 2015 | LGND | LIGAND PHARMACEUTI ... | DeSilva Nishan M | VP, Finance & Strat ... | Sell | S | 83.23 | 12,148 | 1,011,078 | 22,282 | 34.4 K to 22.3 K (-35.28 %) |
May 14 2015 | LGND | LIGAND PHARMACEUTI ... | DeSilva Nishan M | VP, Finance & Strat ... | Buy | M | 21.92 | 12,148 | 266,284 | 34,430 | 22.3 K to 34.4 K (+54.52 %) |
May 14 2015 | LGND | LIGAND PHARMACEUTI ... | DeSilva Nishan M | VP, Finance & Strat ... | Sell | S | 84.91 | 9,306 | 790,172 | 22,282 | 31.6 K to 22.3 K (-29.46 %) |
May 14 2015 | LGND | LIGAND PHARMACEUTI ... | DeSilva Nishan M | VP, Finance & Strat ... | Buy | M | 21.92 | 9,306 | 203,988 | 31,588 | 22.3 K to 31.6 K (+41.76 %) |
May 14 2015 | LGND | LIGAND PHARMACEUTI ... | DeSilva Nishan M | VP, Finance & Strat ... | Sell | S | 84.44 | 14,214 | 1,200,230 | 22,282 | 36.5 K to 22.3 K (-38.95 %) |
May 14 2015 | LGND | LIGAND PHARMACEUTI ... | DeSilva Nishan M | VP, Finance & Strat ... | Buy | M | 14.47 | 14,214 | 205,677 | 36,496 | 22.3 K to 36.5 K (+63.79 %) |
Apr 28 2015 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Option Exercise | A | 89.75 | 2,754 | 247,172 | 2,754 | |
Apr 28 2015 | LGND | LIGAND PHARMACEUTI ... | KNOTT DAVID M | Director | Grant | A | 0.00 | 925 | 0 | 70,152 | 69.2 K to 70.2 K (+1.34 %) |
Apr 27 2015 | LGND | LIGAND PHARMACEUTI ... | Patel Sunil | Director | Option Exercise | A | 89.75 | 2,754 | 247,172 | 2,754 | |
Apr 27 2015 | LGND | LIGAND PHARMACEUTI ... | Patel Sunil | Director | Grant | A | 0.00 | 925 | 0 | 38,025 | 37.1 K to 38 K (+2.49 %) |
Apr 27 2015 | LGND | LIGAND PHARMACEUTI ... | LAMATTINA JOHN L | Director | Option Exercise | A | 89.75 | 2,754 | 247,172 | 2,754 | |
Apr 27 2015 | LGND | LIGAND PHARMACEUTI ... | LAMATTINA JOHN L | Director | Grant | A | 0.00 | 925 | 0 | 20,980 | 20.1 K to 21 K (+4.61 %) |
Apr 27 2015 | LGND | LIGAND PHARMACEUTI ... | KOZARICH JOHN W | Director | Option Exercise | A | 89.75 | 2,754 | 247,172 | 2,754 | |
Apr 27 2015 | LGND | LIGAND PHARMACEUTI ... | KOZARICH JOHN W | Director | Grant | A | 0.00 | 925 | 0 | 50,211 | 49.3 K to 50.2 K (+1.88 %) |
Apr 27 2015 | LGND | LIGAND PHARMACEUTI ... | Davis Todd C | Director | Option Exercise | A | 89.75 | 2,754 | 247,172 | 2,754 | |
Apr 27 2015 | LGND | LIGAND PHARMACEUTI ... | Davis Todd C | Director | Grant | A | 0.00 | 501 | 0 | 35,779 | 35.3 K to 35.8 K (+1.42 %) |
Apr 27 2015 | LGND | LIGAND PHARMACEUTI ... | Davis Todd C | Director | Grant | A | 0.00 | 925 | 0 | 35,278 | 34.4 K to 35.3 K (+2.69 %) |
Apr 27 2015 | LGND | LIGAND PHARMACEUTI ... | Aryeh Jason | Director | Option Exercise | A | 89.75 | 2,754 | 247,172 | 2,754 | |
Apr 27 2015 | LGND | LIGAND PHARMACEUTI ... | Aryeh Jason | Director | Grant | A | 0.00 | 925 | 0 | 58,337 | 57.4 K to 58.3 K (+1.61 %) |
Mar 20 2015 | LGND | LIGAND PHARMACEUTI ... | Patel Sunil | Director | Sell | S | 74.42 | 4,591 | 341,662 | 37,100 | 41.7 K to 37.1 K (-11.01 %) |
Mar 18 2015 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Option Exercise | M | 21.92 | 4,130 | 90,530 | 4,764 | |
Mar 18 2015 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Option Exercise | M | 14.47 | 1,134 | 16,409 | 0 | |
Mar 18 2015 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Sell | S | 74.58 | 4,130 | 308,015 | 25,989 | 30.1 K to 26 K (-13.71 %) |
Mar 18 2015 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Buy | M | 21.92 | 4,130 | 90,530 | 30,119 | 26 K to 30.1 K (+15.89 %) |
Mar 18 2015 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Sell | S | 74.58 | 1,134 | 84,574 | 25,989 | 27.1 K to 26 K (-4.18 %) |
Mar 18 2015 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Buy | M | 14.47 | 1,134 | 16,409 | 27,123 | 26 K to 27.1 K (+4.36 %) |
Mar 18 2015 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Sell | S | 74.51 | 6,000 | 447,060 | 25,989 | 32 K to 26 K (-18.76 %) |
Mar 03 2015 | LGND | LIGAND PHARMACEUTI ... | Herman Melanie J | Director of Account ... | Sell | S | 60.69 | 535 | 32,469 | 2,986 | 3.5 K to 3 K (-15.19 %) |
Feb 20 2015 | LGND | LIGAND PHARMACEUTI ... | Herman Melanie J | Director of Account ... | Sell | S | 57.84 | 510 | 29,498 | 3,521 | 4 K to 3.5 K (-12.65 %) |
Feb 11 2015 | LGND | LIGAND PHARMACEUTI ... | Herman Melanie J | Director of Account ... | Option Exercise | A | 56.26 | 9,000 | 506,340 | 9,000 | |
Feb 11 2015 | LGND | LIGAND PHARMACEUTI ... | Herman Melanie J | Director of Account ... | Grant | A | 0.00 | 1,200 | 0 | 4,031 | 2.8 K to 4 K (+42.39 %) |
Feb 11 2015 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | EVP and COO | Option Exercise | A | 56.26 | 42,113 | 2,369,277 | 42,113 | |
Feb 11 2015 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | EVP and COO | Grant | A | 0.00 | 13,112 | 0 | 68,128 | 55 K to 68.1 K (+23.83 %) |
Feb 11 2015 | LGND | LIGAND PHARMACEUTI ... | DeSilva Nishan M | VP, Corporate Devel ... | Option Exercise | A | 56.26 | 20,873 | 1,174,315 | 20,873 | |
Feb 11 2015 | LGND | LIGAND PHARMACEUTI ... | DeSilva Nishan M | VP, Corporate Devel ... | Grant | A | 0.00 | 5,923 | 0 | 22,282 | 16.4 K to 22.3 K (+36.21 %) |
Feb 11 2015 | LGND | LIGAND PHARMACEUTI ... | DeSilva Nishan M | VP, Corporate Devel ... | Sell | S | 56.34 | 2,300 | 129,582 | 16,359 | 18.7 K to 16.4 K (-12.33 %) |
Feb 11 2015 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Option Exercise | A | 56.26 | 16,057 | 903,367 | 16,057 | |
Feb 11 2015 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | VP, Gen. Counsel & ... | Grant | A | 0.00 | 4,556 | 0 | 31,989 | 27.4 K to 32 K (+16.61 %) |